| HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. | |
| | |
MedLine Citation:
|
PMID: 23348520 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
Background:In metastatic colorectal cancer (mCRC), KRAS is the only validated biomarker used to select patients for administration of epidermal growth factor receptor (EGFR)-targeted therapies. To identify additional predictive markers, we investigated the importance of HER2, the primary EGFR dimerisation partner, in this particular disease.Methods:We evaluated the HER2 gene status by fluorescence in situ hybridisation (FISH) in 170 KRAS wild-type mCRC patients treated with cetuximab or panitumumab.Results:Depending on HER2 gene copy number status, patients showed three distinct cytogenetic profiles: 4% of patients had HER2 gene amplification (R:HER2/CEP172) in all neoplastic cells (HER2-all-A), 61% of patients had HER2 gain due to polysomy or to gene amplification in minor clones (HER2-FISH+*), and 35% of patients had no or slight HER2 gain (HER2-FISH-). These subgroups were significantly correlated with different clinical behaviours, in terms of response rate (RR; P=0.0006), progression-free survival (PFS; P<0.0001) and overall survival (OS; P<0.0001). Patients with HER2-all-A profile experienced the worst outcome, patients with HER2-FISH- profile showed an intermediate behaviour and patients with HER2-FISH+* profile were related to the highest survival probability (median PFS in months: 2.5 vs 3.9 vs 7.6, respectively; median OS in months: 4.2 vs 9.7 vs 13, respectively).Conclusion:HER2 gene copy number status may influence the clinical response to anti-EGFR-targeted therapy in mCRC patients.British Journal of Cancer advance online publication, 24 January 2013; doi:10.1038/bjc.2013.4 www.bjcancer.com. |
| | |
Authors:
|
V Martin; L Landi; F Molinari; G Fountzilas; R Geva; A Riva; P Saletti; S De Dosso; A Spitale; S Tejpar; K T Kalogeras; L Mazzucchelli; M Frattini; F Cappuzzo |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2013-1-24 |
Journal Detail:
|
Title: British journal of cancer Volume: - ISSN: 1532-1827 ISO Abbreviation: Br. J. Cancer Publication Date: 2013 Jan |
Date Detail:
|
Created Date: 2013-1-25 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0370635 Medline TA: Br J Cancer Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
Institute of Pathology, Locarno 6600, Switzerland. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The etiology of uterine sarcomas: a pooled analysis of the epidemiology of endometrial cancer consor...
Next Document: Environmental Factors and Quality Improvement in County and Local Health Departments.